BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Difficulty in establishing a diagnosis in an uncommon presentation of a minor salivary gland tumour.

We report the case of a man presenting with a large, airway obstructing, minor salivary gland tumour arising from the right tonsillar base.

A firm diagnosis of malignancy could not be made histologically.

The differential diagnosis included polymorphous low-grade adenocarcinoma, basal cell adenoma and adenoid cystic carcinoma.

However, on balance, based on the clinical presentation, a diagnosis of malignancy was favoured and appropriate treatment was considered.

[MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Airway Obstruction / etiology. Deglutition Disorders / etiology. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor. Tongue Neoplasms / diagnosis

[MeSH-minor] Biomarkers, Tumor / analysis. Biopsy. Cooperative Behavior. Diagnosis, Differential. Endoscopy. Humans. Interdisciplinary Communication. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiotherapy. Magnetic Resonance Imaging. Male. Middle Aged. Palliative Care. Tongue / pathology. Tracheostomy

MedlinePlus Health Information. consumer health - Choking.

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]

[Cites] Am J Surg. 1991 Oct;162(4):330-6 [1659242.001]

[Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):443-54 [8655366.001]

[Cites] Cancer Treat Rev. 1996 Nov;22(6):395-423 [9134002.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Apr;87(4):485-92 [10225632.001]

[Cites] Ann Surg. 1956 Sep;144(3):366-83 [13363274.001]

[Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]

(PMID = 22798299.001).

[ISSN] 1757-790X

[Journal-full-title] BMJ case reports

[ISO-abbreviation] BMJ Case Rep

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor

[Other-IDs] NLM/ PMC3029651

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma in the tongue: an unusual presentation.

We present a case of basal cell adenocarcinoma (BCAC) in the tongue in a 65-year old male.

BCAC generally occurs in the parotid gland and rarely involves the minor salivary glands.

The clinicopathological features and the cellular immunophenotype addressed the diagnosis towards BCAC of the tongue.

The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21151583.001).

[ISSN] 1179-5549

[Journal-full-title] Clinical Medicine Insights. Oncology

[ISO-abbreviation] Clin Med Insights Oncol

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2999957

[Keywords] NOTNLM ; basal cell adenocarcinoma / minor salivary gland / tongue

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Carbon ion radiotherapy for basal cell adenocarcinoma of the head and neck: preliminary report of six cases and review of the literature.

BACKGROUND: Basal cell adenocarcinoma accounts for approximately 1.6% of all salivary gland neoplasms.

METHODS: Case records of 6 patients with diagnosis of basal cell adenocarcinoma of the head and neck, who were treated by carbon ion radiotherapy with 64.0 GyE/16 fractions in our institution, were retrospectively reviewed.

CONCLUSIONS: Carbon ion radiotherapy should be considered as an appropriate curative approach for treatment of basal cell adenocarcinoma in certain cases, particularly in cases of unresectable disease and postoperative gross residual or recurrent disease.

[MeSH-major] Adenocarcinoma / radiotherapy. Carbon / therapeutic use. Head and Neck Neoplasms / radiotherapy. Heavy Ions / therapeutic use

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):737-43 [11020570.001]

[Cites] Histopathology. 2003 Jun;42(6):610-4 [12786899.001]

[Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]

[Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]

[Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]

[Cites] Am J Clin Oncol. 1992 Oct;15(5):441-5 [1326226.001]

[Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]

[Cites] Cancer. 1998 Feb 1;82(3):439-47 [9452259.001]

[Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]

[Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):201-10 [10219815.001]

[Cites] Cancer. 2005 Jul 1;104(1):71-82 [15915466.001]

[Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):396-401 [16182466.001]

[Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]

(PMID = 20920325.001).

[ISSN] 1748-717X

[Journal-full-title] Radiation oncology (London, England)

[ISO-abbreviation] Radiat Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 7440-44-0 / Carbon

[Other-IDs] NLM/ PMC2958970

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenoma of the parotid gland. Case report and review of the literature.

Basal cell adenoma of the salivary glands is an uncommon type of monomorphous adenoma.

Its most frequent location is the parotid gland.

Histologically, isomorphic cells in nests and interlaced trabecules with a prominent basal membrane are observed.

It is also characterized by the presence of a slack and hyaline stroma and the absence of myxoid or condroid stroma.

Due to prognostic implications, differential diagnosis with basal cell adenocarcinoma, adenoid cystic carcinoma and basaloid squamous cell carcinoma is mandatory.

We describe a case of basal cell adenoma of the parotid gland.

We also review the literature and discuss the diagnosis and management of this rare entity.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16505803.001).

[ISSN] 1698-6946

[Journal-full-title] Medicina oral, patología oral y cirugía bucal

[ISO-abbreviation] Med Oral Patol Oral Cir Bucal

[Language] eng; spa

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Spain

[Number-of-references] 21

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma of minor salivary glands.

Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.

The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.

Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.

It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.

Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.

Radiotherapy has been proposed for lesions in the minor salivary glands because of the higher likelihood of vascular and neural invasion and for those that are diffusely infiltrative.

[MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology

[MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17922602.001).

[ISSN] 1543-2165

[Journal-full-title] Archives of pathology & laboratory medicine

[ISO-abbreviation] Arch. Pathol. Lab. Med.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bilateral Basal cell adenocarcinoma of the parotid gland: in a recipient of kidney transplant.

We report a rare case of bilateral basal cell adenocarcinoma (BcAC) of the parotid gland in a male patient 30 years after kidney transplantation and continuous administration of immunosuppressive therapy.

BcAC is a salivary gland malignancy first recognized as a distinct neoplastic entity in WHO classification of salivary gland tumours in 1991.

Over 90% of BcACs are detected in the parotid gland.

The most important differential diagnosis is basal cell adenoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21151548.001).

[ISSN] 1179-5557

[Journal-full-title] Clinical medicine insights. Pathology

[ISO-abbreviation] Clin Med Insights Pathol

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Other-IDs] NLM/ PMC2999998

[Keywords] NOTNLM ; basal cell adenocarcinoma / immunohistochemistry / post transplantation malignancy / salivary gland cancer

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma of a hard palate minor salivary gland: case report and review of the literature.

OBJECTIVE: Basal cell adenocarcinoma of a minor salivary gland is extremely rare.

The goal of this report is to increase awareness of this rare disease and to review and discuss the differential diagnosis and important considerations in treatment.

METHODS: Case report of a basal cell adenocarcinoma of a hard palate minor salivary gland and review of the literature of basal cell adenocarcinoma.

RESULTS: Basal cell adenocarcinomas are slow-growing tumours that most commonly involve the parotid gland and very rarely involve minor salivary glands.

Histological diagnosis is important to distinguish this tumour from adenoid cystic carcinoma given the significant difference in disease prognosis.

CONCLUSIONS: Diagnosis of these tumours must be made histologically.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Arch Otolaryngol. 1978 Feb;104(2):111-6 [629699.001]

[Cites] J Oral Pathol. 1985 Jul;14(6):500-9 [2991488.001]

[Cites] Arch Pathol Lab Med. 1988 Feb;112(2):209-11 [2827601.001]

[Cites] J Laryngol Otol. 1989 Aug;103(8):756-9 [2769045.001]

[Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):461-9 [2326038.001]

[Cites] Cancer. 1996 Dec 15;78(12):2471-7 [8952553.001]

[Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]

[Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]

[Cites] Int J Oral Maxillofac Surg. 2005 Jul;34(5):528-32 [16053873.001]

[Cites] Int J Oral Maxillofac Surg. 2006 Feb;35(2):150-4 [16181771.001]

[Cites] Med Oral Patol Oral Cir Bucal. 2006 Mar;11(2):E206-9 [16505803.001]

[Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jan;103(1):77-84 [17178498.001]

[Cites] J Oral Pathol Med. 2007 Apr;36(4):207-14 [17391298.001]

[Cites] Acta Otolaryngol. 1998 Jul;118(4):588-93 [9726688.001]

(PMID = 20030819.001).

[ISSN] 1758-3284

[Journal-full-title] Head & neck oncology

[ISO-abbreviation] Head Neck Oncol

[Language] ENG

[Grant] United States / NIDCR NIH HHS / DE / K08 DE018061

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] England

[Other-IDs] NLM/ PMC2806868

[General-notes] NLM/ Original DateCompleted: 20100629

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Well-differentiated basal cell adenocarcinoma of the lacrimal sac: a case report].

[Transliterated title] Adenocarcinoma de células basales del saco lacrimal bien diferenciado. A propósito de un caso.

Basal cell adenocarcinoma is a rare tumor first considered to be a separate entity by the WHO in 1991.

We present a case of adenocarcinoma of the lacrimal sac diagnosed at histological study.

We discuss the differential diagnosis and treatment for this tumor.

[MeSH-major] Adenocarcinoma / diagnosis. Lacrimal Apparatus

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17524341.001).

[ISSN] 0033-8338

[Journal-full-title] Radiología

[ISO-abbreviation] Radiologia

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Spain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma of the ethmoid sinuses.

Basal cell adenocarcinoma is a rare and relatively recently characterised malignant salivary gland tumour.

It accounts for 5 per cent of parotid gland tumours and 1 per cent of salivary gland malignancies.

It is very rarely documented in anatomical sites other than the major salivary glands.

Basal cell adenocarcinoma has only been described once before in the ethmoid sinus.

We report a case of basal cell adenocarcinoma in the ethmoid sinus, extending into the right orbit and anterior cranial fossa.

We describe the clinical aspects of the patient's management and detail the histopathological features of this very rare diagnosis.

[MeSH-major] Adenocarcinoma. Ethmoid Sinus. Paranasal Sinus Neoplasms

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17295935.001).

[ISSN] 1748-5460

[Journal-full-title] The Journal of laryngology and otology

[ISO-abbreviation] J Laryngol Otol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A case of basal cell adenocarcinoma of the upper gingiva.

Basal cell adenocarcinoma arising from the minor salivary gland is extremely rare.

We report a 76-year-old Japanese man with basal cell adenocarcinoma originating in the upper gingiva.

[MeSH-major] Adenocarcinoma / surgery. Gingival Neoplasms / surgery. Maxillary Neoplasms / surgery. Oral Surgical Procedures. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery

[MeSH-minor] Aged. Humans. Male. Salivary Glands, Minor / pathology. Salivary Glands, Minor / surgery. Surgical Flaps

MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19157926.001).

[ISSN] 1528-395X

[Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics

[ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Basal cell adenocarcinoma of nasal septum: a case report and review of literatures].

OBJECTIVE: To summarize clinical features, diagnosis, differential diagnosis, treatment and prognosis of basal cell adenocarcinoma.

METHOD: A retrospective study were subjected to one case with basal cell adenocarcinoma of the nasal septum, and the related literature were reviewed.

RESULT: Basal cell adenocarcinoma often occurred in the salivary glands and minor salivary glands of salivary palate and other parts.

CONCLUSION: Basal cell adenocarcinoma is rare seen in the salivary gland tumors.

It has a tendency of low-grade malignancy but need long-term follow-up of a large samples.

[MeSH-major] Adenocarcinoma. Nasal Septum / pathology. Nose Neoplasms

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19522187.001).

[ISSN] 1001-1781

[Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery

[ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

[Language] chi

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Cytogenetic and fluorescence in situ hybridization analysis of a basal cell adenocarcinoma of the mandible.

Basal cell adenocarcinoma (BCAC) of the salivary glands is rare.

Distant metastasis to the mandible from a salivary gland tumor is also considered rare.

The cytogenetic finding of a case of metastatic BCAC of the mandible is described.

An 80-year-old female with primary BCAC of the parotid salivary gland underwent parotidectomy and chemotherapy.

The characteristic histologic architecture of BCAC found in the mandible was similar to that of the earlier findings of the tumor in the parotid gland.

[MeSH-major] Adenocarcinoma / genetics. Mandibular Neoplasms / genetics

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16631478.001).

[ISSN] 0165-4608

[Journal-full-title] Cancer genetics and cytogenetics

[ISO-abbreviation] Cancer Genet. Cytogenet.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma of the oral minor salivary glands: review of the literature and presentation of two cases.

Basal cell adenocarcinoma (BCA) is an unusual salivary gland malignancy that very rarely affects the minor glands.

Here we present 2 cases of BCA arising in the minor salivary glands of the left cheek and junction of the hard and soft palate, respectively.

A comprehensive literature review revealed only 21 previously reported cases of BCA of oral minor salivary glands.

This is an exceptionally rare salivary gland tumor, which, despite its low-grade behavior, demands complete surgical removal with adequate margins.

Immunohistochemical studies may complement a thorough histopathologic analysis in discriminating BCA from other salivary gland tumors.

[MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17178498.001).

[ISSN] 1528-395X

[Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics

[ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] United States

[Number-of-references] 35

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Basal cell adenocarcinoma of the sublingual gland].

The cause of a swelling in the floor of the mouth will in most cases be benign.

Tumors of the sublingual gland are very rare, but 90% are malignant and therefore malignancy should always be excluded in case of an asymptomatic swelling covered by intact mucosa.

[MeSH-major] Adenocarcinoma / pathology. Sublingual Gland Neoplasms / pathology

[MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Edema / diagnosis. Female. Humans. Middle Aged

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20156409.001).

[ISSN] 1603-6824

[Journal-full-title] Ugeskrift for laeger

[ISO-abbreviation] Ugeskr. Laeg.

[Language] dan

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Denmark

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Synchronous double primary cancers of the unilateral parotid gland.

To the best of our knowledge, there has been no report of synchronous unilateral double primary carcinomas of the parotid gland.

Here we report a 39-year-old woman who exhibited basal cell adenocarcinoma and mucoepidermoid carcinoma simultaneously in the left parotid gland.

[MeSH-major] Adenocarcinoma / pathology. Carcinoma, Mucoepidermoid / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17364354.001).

[ISSN] 0001-6489

[Journal-full-title] Acta oto-laryngologica

[ISO-abbreviation] Acta Otolaryngol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Norway

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Skin type spiradenoma of the parotid gland with malignant transformation: report of a case with analysis of the CYLD gene.

A distinctive variant of basal cell adenoma called membranous basal cell adenoma is well recognized in salivary glands.

We present a case of a tumor involving the parotid gland that appeared identical to cutaneous spiradenoma.

In addition, the lesion had a malignant component identical to basal cell adenocarcinoma.

This is the first report of a "dermal analogue tumor" of the salivary gland that resembled a cutaneous spiradenoma and not a cylindroma.

[MeSH-minor] Aged. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. DNA Mutational Analysis. Female. Humans

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19454360.001).

[ISSN] 1532-8392

[Journal-full-title] Human pathology

[ISO-abbreviation] Hum. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CYLD protein, human; 0 / Tumor Suppressor Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fine-needle aspiration cytology of basal cell adenoma of the parotid gland: characteristic cytological features and diagnostic pitfalls.

We retrospectively studied the cytological features of aspiration cytology in 12 cases of basal cell adenoma (BCA) and 5 cases mistakenly diagnosed as BCA.

The characteristic cytological features of solid type BCA were three-dimensional clusters in 71%, sharp-angle small clusters in 86%, basement membrane- like material in 71%, and cell crush in 86%.

In contrast, 3 of the 5 cystic type BCA cases showed inadequate cellular components or no basaloid tumor cells, and the cytological diagnosis of BCA could not be determined.

In the 5 cases misdiagnosed as BCA, there were 2 cases of pleomorphic adenoma, 2 cases of benign lymphoepithelial cyst, and 1 case of basal cell adenocarcinoma.

Accurate differential cytological diagnosis of BCA is relatively easy to determine the solid type BCA, but is more difficult for cystic type BCA.

[MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis

[MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Male. Middle Aged. Prospective Studies

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17230571.001).

[ISSN] 8755-1039

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Diagnostic difficulties in the interpretation of fine needle aspirate samples in salivary lesions: diagnostic pitfalls revisited.

OBJECTIVE: To present our experience in diagnostic errors and pitfalls on aspiration cytology of salivary region in a high volume of cases.

STUDY DESIGN: In a retrospective review of cytology files of a head and neck referral center from 1990 to 2005, the false positive and false negative interpretations on fine needle aspiration (FNA) of salivary lesions were retrieved.

These records and slides were reviewed to identify cytologic characteristics that contributed to false diagnosis.

RESULTS: Of a total of 1,040 salivary FNA samples, 376 cases had a final histologic diagnosis with interpretations of benign or malignant.

The most common false negative cases were acinic cell carcinoma, epithelial myoepithelial carcinoma, adenoid cystic carcinoma and basal cell adenocarcinoma.

Benign cases with false positive diagnosis were Warthin tumor and pleomorphic adenoma.

CONCLUSION: Knowledge of cytologic overlaps and pitfalls on salivary gland FNA, as well as clinical and radiologic features, may help clinicians arrive at the appropriate diagnosis and reduce false interpretations.

[MeSH-major] Salivary Gland Neoplasms / diagnosis. Salivary Glands / pathology

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Child. Child, Preschool. Diagnosis, Differential. False Negative Reactions. False Positive Reactions. Female. Humans. Infant. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Young Adult

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19248555.001).

[ISSN] 0001-5547

[Journal-full-title] Acta cytologica

[ISO-abbreviation] Acta Cytol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

CD43 immunoreactivity with 2 different antibodies was detected mainly in ACC but also 1 membranous type basal cell adenocarcinoma and 1 colonic adenocarcinoma.

Nine of 20 (45%) ACC (8/17 salivary/mucoserous and 1/3 mammary) showed immunoreactivity with clone MT1 whereas 4 (23.5%) salivary ACC also showed immunoreactivity with clone DF-T1.

Hence, CD43 seems to be selectively expressed in a subset of ACC and its significance in salivary tumors is discussed.

Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18227725.001).

[ISSN] 1541-2016

[Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM

[ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD43; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Parotid basal cell adenoma of membranous type].

[Transliterated title] Adenome a cellules basales de type membraneux de la parotide.

INTRODUCTION: Basal cell adenoma (BCA) is a rare benign neoplasm characterized by the basaloid appearance of the tumour cells and the lack of myxo-chondroid stromal component present in pleomorphic adenoma.

AIM: We report a case of basal cell adenoma of membranous type, highly suspected of malignancy because of the presence of mediastinal lymph nodes and pulmonary nodules which finally were related to an associated sarcoidosis.

So the diagnosis of metastatic malignant salivary gland tumor was suspected.

Finally, the histological examination concluded to a basal cell adenoma of membranous type with sarcoidosis granulomas in the parotid and in the lymph nodes.

CONCLUSION: The BCA is a benign tumor located generally in the parotid gland.

When the malignancy is suspected, like in our case, this tumor must be differentiated from the basal cell adenocarcinoma using histological criteria.

[MeSH-major] Adenoma / diagnosis. Parotid Neoplasms / diagnosis. Sarcoidosis / diagnosis

[MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis. Mediastinum / radiography. Treatment Outcome

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19522450.001).

[ISSN] 0041-4131

[Journal-full-title] La Tunisie médicale

[ISO-abbreviation] Tunis Med

[Language] fre

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Tunisia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical presentation of oral basaloid squamous cell carcinoma.

AIM: The purpose of this report is to present the clinical and histological features of a basaloid squamous cell carcinoma (BSCC) occurring in the retromolar trigone of a 59-year-old man and to relate its immunohistochemical characteristics.

BACKGROUND: BSCC is an aggressive distinct variant of squamous cell carcinoma (SCC) requiring recognition as a separate entity from SCC due to its peculiar behavior.

SUMMARY: Since this tumor can mimic other neoplasms such as adenoid cystic carcinoma, neuroendocrine carcinoma, and basal cell adenocarcinoma, histological features are essential to differentiate between them.

Clinicians are advised to conduct a mucosal evaluation during oral examinations and take a thorough medical history which could ultimately save the life of a patient.

[MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Mouth Neoplasms / diagnosis

[MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Cell Nucleus / ultrastructure. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Keratins / analysis. Ki-67 Antigen / analysis. Laminin / analysis. Male. Middle Aged. Mitosis. Necrosis. Tumor Suppressor Protein p53 / analysis

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

Genetic Alliance. consumer health - Oral squamous cell carcinoma.

MedlinePlus Health Information. consumer health - Oral Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19279978.001).

[ISSN] 1526-3711

[Journal-full-title] The journal of contemporary dental practice

[ISO-abbreviation] J Contemp Dent Pract

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Laminin; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Two cases of a distinctive variety of basaloid squamous carcinoma (BSC) of the anal canal are described.

The histologic differential diagnosis is true salivary gland-type adenoid cystic carcinoma and basal cell adenocarcinoma.

Immunohistochemistry and awareness of this unusual pattern of BSC will facilitate the correct diagnosis being reached.

[MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Basosquamous / pathology

[MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Cell Nucleus / metabolism. Cisplatin / therapeutic use. DNA-Binding Proteins. Female. Fluorouracil / therapeutic use. Follow-Up Studies. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Middle Aged. Mitomycin / therapeutic use. Phosphoproteins / metabolism. Radiotherapy. Time Factors. Trans-Activators / metabolism. Transcription Factors. Treatment Outcome. Tumor Burden. Tumor Suppressor Proteins

Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

Hazardous Substances Data Bank. MITOMYCIN C .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16327441.001).

[ISSN] 0147-5185

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 50SG953SK6 / Mitomycin; 68238-35-7 / Keratins; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Malignant salivary gland tumors and cyclo-oxygenase-2: a histopathological and immunohistochemical analysis with implications on histogenesis.

The classification system for malignant salivary gland tumors (MST) is largely dependent on its histogenesis.

Fifty six primary major and minor gland MST were stained with anti-cox-2 antibody and rated with a combined score that added a scale of intensity to the percentage of tumor cells that overexpressed the cox-2 protein.

Strong cox-2 overexpression was noted in all MST of proposed excretory duct origin: salivary duct carcinoma (100%), mucoepidermoid carcinoma (MEC) (92%), and adenocarcinoma nos (AdC nos) (83%).

Primary squamous cell carcinoma (PSCC) was the exception.

Negative expression was noted in all tumors of proposed intercalated duct origin (adenoid cystic carcinoma, basal cell adenocarcinoma and acinic cell carcinoma) with the exception of one case of polymorphous low grade adenocarcinoma.

Strong cox-2 overexpression was noted in the epidermoid cells of MEC, abluminal duct cells surrounding the duct-like structures and ductal cells of AdC nos and salivary duct carcinoma.

[MeSH-major] Biomarkers, Tumor / analysis. Cyclooxygenase 2 / analysis. Salivary Gland Neoplasms / enzymology. Salivary Gland Neoplasms / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19729335.001).

[ISSN] 1879-0593

[Journal-full-title] Oral oncology

[ISO-abbreviation] Oral Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell adenocarcinoma arising from the minor salivary gland in the soft palate: a case report.

Basal cell adenocarcinomas (BCACs) of the oral minor salivary gland are very rare neoplasms.

We report on an 86-year-old woman with BCAC arising from the minor salivary gland in the soft palate.

[MeSH-major] Adenocarcinoma / pathology. Palate, Soft / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands, Minor / pathology

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16487667.001).

[ISSN] 0344-0338

[Journal-full-title] Pathology, research and practice

[ISO-abbreviation] Pathol. Res. Pract.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basaloid squamous cell carcinoma: two case reports.

Basaloid squamous cell carcinoma (BSCC) is a rare and aggressive variant of squamous cell carcinoma (SCC) that occurs preferentially in the upper aerodigestive tract.

BSCC of the head and neck should be distinguished from adenoid cystic carcinoma, small cell neuroendocrine carcinoma, basal cell adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid cystic carcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Eur J Cancer. 2008 Jan;44(2):244-50 [18096379.001]

[Cites] Auris Nasus Larynx. 2007 Mar;34(1):119-23 [17141998.001]

[Cites] Histopathology. 2000 Sep;37(3):218-23 [10971697.001]

[Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]

[Cites] Ophthalmology. 1993 Nov;100(11):1720-2 [8233401.001]

(PMID = 20062602.001).

[ISSN] 1757-1626

[Journal-full-title] Cases journal

[ISO-abbreviation] Cases J

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC2804002

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Fine needle aspiration cytology of basal cell adenoma of the salivary gland.

OBJECTIVE: To formulate cytologic features for differential diagnosis of basal cell adenoma (BCA).

STUDY DESIGN: The usefulness of 5 items for a cytologically definitive diagnosis of BCA was examined.

The 5 items in 8 BCA and 22 non-BCA cases (adenoid cystic carcinoma [ADCC], basal cell adenocarcinoma, myoepithelioma, pleomorphic adenoma and polymorphous low-grade adenocarcinoma) that displayed mimicking cytology were examined cytologically.

RESULTS: The useful items were < 5.1 microm in mean of epithelial nuclear short diameter; mild atypia on definitive diagnosis; stromal cell cluster combining smooth margin surrounding the epithelial cell cluster or containing the epithelial cell cluster; epithelial clusters surrounded by or adhered to a thick, hyalinized smooth margin without stromal cluster; and closely fastened, tight clusters with denser cytoplasm than ADCC, but an indistinct border, with oval nuclei and no hyaline cells.

[MeSH-major] Adenoma / pathology. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology

[MeSH-minor] Adenocarcinoma / pathology. Biopsy, Fine-Needle. Carcinoma, Adenoid Cystic / pathology. Cell Nucleus / pathology. Diagnosis, Differential. Epithelium / pathology. Epithelium / ultrastructure. Humans. Immunohistochemistry. Myoepithelioma / pathology. Organelle Size. Stromal Cells / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17910337.001).

[ISSN] 0001-5547

[Journal-full-title] Acta cytologica

[ISO-abbreviation] Acta Cytol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intraoral minor salivary gland tumors: a clinicopathological study of 82 cases.

We present a retrospective study of 82 patients with intraoral minor salivary gland tumors which were diagnosed from 1979 to 2003 in Gifu University Hospital.

Histologically, the tumors were classified as pleomorphic adenoma (n = 54), papillary cystadenoma (n = 1), adenoid cystic carcinoma (n = 10), mucoepidermoid carcinoma (n = 8), acinic cell carcinoma (n = 3), adenocarcinoma (n = 2), basal cell adenocarcinoma (n = 1), papillary cystadenocarcinoma (n = 1), and carcinoma in pleomorphic adenoma (n = 2).

From the results of the present study and review of the literature, it is suggested that the minor salivary gland tumors in Japan may be characterized by a higher incidence of benign tumors, especially of pleomorphic adenoma; a more marked tendency for female predominance; a higher incidence of palatal involvement; and a rarer occurrence of polymorphous low grade adenocarcinoma, in comparison with those reported in the literature from outside of Japan.

[MeSH-major] Salivary Gland Neoplasms / epidemiology. Salivary Glands, Minor / pathology

[MeSH-minor] Adenocarcinoma / epidemiology. Adenoma, Pleomorphic / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Mucoepidermoid / epidemiology. Cheek / pathology. Child. Female. Humans. Japan / epidemiology. Lip / pathology. Male. Middle Aged. Palate / pathology. Retrospective Studies. Sex Factors

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16053873.001).

[ISSN] 0901-5027

[Journal-full-title] International journal of oral and maxillofacial surgery

[ISO-abbreviation] Int J Oral Maxillofac Surg

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Denmark

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.

Early diagnosis and proper treatment significantly improve the outcome.

SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).

Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.

[MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism

[MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20551262.001).

[ISSN] 1943-7722

[Journal-full-title] American journal of clinical pathology

[ISO-abbreviation] Am. J. Clin. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Atypical sclerosing adenosis of the prostate: a rare mimic of adenocarcinoma.

AIMS: Sclerosing adenosis of the prostate is a benign, small, acinar proliferation in dense spindle cell stroma, with a distinct immunohistochemical profiles.

METHODS AND RESULTS: We describe five cases of sclerosing adenosis with significant cytological atypia, referred to as atypical sclerosing adenosis (ASA), which were initially considered suspicious or diagnostic of adenocarcinoma.

All cases of typical and atypical sclerosing adenosis displayed an intact basal cell layer, which was immunoreactive for high-molecular-weight keratin, S100 protein, smooth muscle actin, and prostate-specific antigen, with no differences between ASA and the control group.

CONCLUSIONS: ASA is an unusual small, acinar proliferation of the prostate that may be mistaken for adenocarcinoma, and should be distinguished from other mimics, including atypical adenomatous hyperplasia, mesonephric remnant hyperplasia, and post-atrophic hyperplasia.

[MeSH-major] Adenocarcinoma / diagnosis. Prostatic Diseases / diagnosis. Prostatic Hyperplasia / diagnosis

[MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Needle. Diagnosis, Differential. Humans. Male. Middle Aged. Sclerosis

MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20459573.001).

[ISSN] 1365-2559

[Journal-full-title] Histopathology

[ISO-abbreviation] Histopathology

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.

In epithelial cancers, such as those of the breast, the epithelial-mesenchymal transition (EMT) is associated with basal-like breast cancers, generates cells with stem-like properties, and enables cancer cell dissemination and metastasis.

However, the molecular mechanism(s) that connects stem cell-like characteristics with EMT has yet to be defined.

The wnt genes identified in this signature were strongly associated with human basal-like breast cancers.

Collectively, these results provide a molecular link between self-renewal, EMT, and metastasis in basal-like breast cancers.

Genetic Alliance. consumer health - Lung Cancer.

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Lung Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):153-62 [17566854.001]

[Cites] Oncogene. 2007 Aug 16;26(38):5680-91 [17353908.001]

[Cites] J Cell Biochem. 2007 Dec 15;102(6):1519-28 [17471511.001]

[Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19506-11 [18048329.001]

[Cites] Br J Cancer. 2008 Mar 25;98(6):1147-56 [18283316.001]

[Cites] Cancer Res. 2008 May 1;68(9):3108-14 [18451135.001]

[Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]

[Cites] Breast Cancer Res. 2008;10(2):R25 [18366788.001]

[Cites] Clin Exp Metastasis. 2008;25(6):629-42 [18461285.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6 [10759547.001]

[Cites] J Biol Chem. 2001 Aug 10;276(32):30350-8 [11402039.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]

[Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]

[Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]

[Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]

[Cites] Breast Cancer Res. 2003;5(2):101-6 [12631389.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]

[Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]

[Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]

[Cites] Cancer Res. 2003 Sep 15;63(18):5679-84 [14522883.001]

[Cites] J Cell Biol. 2003 Nov 24;163(4):847-57 [14623871.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15901-5 [14665696.001]

[Cites] Neoplasia. 2004 Jan-Feb;6(1):1-6 [15068665.001]

[Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]

[Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]

[Cites] Int J Oncol. 2004 Sep;25(3):641-9 [15289865.001]

[Cites] Cell. 2004 Aug 6;118(3):277-9 [15294153.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13756-61 [15356343.001]

[Cites] Int J Cancer. 2005 Feb 10;113(4):515-24 [15472907.001]

[Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]

[Cites] Cancer Res. 2005 Jul 15;65(14):6130-8 [16024614.001]

[Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]

[Cites] Cancer Biol Ther. 2005 Apr;4(4):365-70 [15846061.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13550-5 [16141321.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14 [16172383.001]

[Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]

[Cites] Mol Biol Cell. 2005 Nov;16(11):5283-93 [16135532.001]

[Cites] J Leukoc Biol. 2006 Feb;79(2):339-50 [16282532.001]

[Cites] Breast Cancer Res. 2005;7(6):R953-64 [16280042.001]

[Cites] Cancer Cell. 2006 Feb;9(2):121-32 [16473279.001]

[Cites] Cancer Biol Ther. 2006 Mar;5(3):281-6 [16410723.001]

[Cites] BMC Genomics. 2006;7:96 [16643655.001]

[Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]

[Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]

[Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]

[Cites] Nat Cell Biol. 2006 Dec;8(12):1398-406 [17072303.001]

[Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]

[Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]

[Cites] Breast Cancer Res. 2006;8(5):R59 [17062128.001]

[Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]

[Cites] Clin Cancer Res. 2007 Jun 1;13(11):3207-14 [17545524.001]

[Cites] Genome Biol. 2007;8(5):R76 [17493263.001]

[ErratumIn] Cancer Res. 2009 Aug 1;69(15):6366. Feng, Chang [corrected to Fan, Cheng]

(PMID = 19549913.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA125554-02; United States / NCI NIH HHS / CA / R01 CA125554; United States / NCI NIH HHS / CA / R01 CA125554-02; United States / NCI NIH HHS / CA / R01CA12555

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Transcription Factors; 0 / Twist Transcription Factor; 0 / Wnt Proteins; 0 / snail family transcription factors

[Other-IDs] NLM/ NIHMS154900; NLM/ PMC2782448

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Simultaneous exposure to dietary acrylamide and corn oil developed carcinogenesis through cell proliferation and inhibition of apoptosis by regulating p53-mediated mitochondria-dependent signaling pathway.

Colonic apoptosis and cell proliferation, expression of Wild type (wt) p53, Bcl-2, Bax and caspase-3, were detected at 48 week post ACR-exposure.

Apoptosis was decreased and cell proliferation was increased in colonic mucosa in ACR-treated rats on dietary corn oil compared to vehicle rats on basal diet (P < 0.05).

[MeSH-major] Acrylamide / toxicity. Apoptosis / drug effects. Cell Proliferation / drug effects. Corn Oil / administration & dosage. Gene Expression Regulation, Neoplastic / drug effects. Precancerous Conditions / chemically induced. Tumor Suppressor Protein p53 / genetics

[MeSH-minor] Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Animals. Carcinogenicity Tests. Cocarcinogenesis. Colon / drug effects. Colon / pathology. Colonic Neoplasms / chemically induced. Colonic Neoplasms / pathology. Diet. Injections, Intraperitoneal. Intestinal Mucosa / drug effects. Intestinal Mucosa / pathology. Male. Mitochondria / drug effects. Mitochondria / metabolism. Rats. Rats, Sprague-Dawley. Signal Transduction / drug effects

Hazardous Substances Data Bank. ACRYLAMIDE .

Hazardous Substances Data Bank. Corn oil .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19458132.001).

[ISSN] 0748-2337

[Journal-full-title] Toxicology and industrial health

[ISO-abbreviation] Toxicol Ind Health

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 20R035KLCI / Acrylamide; 8001-30-7 / Corn Oil

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Melanoma was the most common (n=12), followed by squamous cell carcinoma (SCC) (n=5).

There were 3 basal cell carcinomas and 2 cases each of sebaceous carcinoma, Paget's disease of the breast and lymphoma.

There were single cases of eccrine carcinoma, malignant trichilemmal tumor, undifferentiated carcinoma and extramedullary myeloid cell tumor.

[MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Cytodiagnosis. Humans. Lymphatic Metastasis. Medical Records. Melanoma / pathology. Paget's Disease, Mammary / pathology

MedlinePlus Health Information. consumer health - Skin Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19068675.001).

[ISSN] 0001-5547

[Journal-full-title] Acta cytologica

[ISO-abbreviation] Acta Cytol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ductal adenocarcinoma of the prostate: current opinion and controversies.

OBJECTIVE: To evaluate the morphologic spectrum and clinical significance of ductal adenocarcinoma of the prostate (DAP).

STUDY DESIGN: We reviewed diagnostic criteria, including the value of immunohistochemistry, and outlined the prognostic implications of a diagnosis of DAP.

A basal cell layer can be seen in some of these tumors, which is probably due to tumor growth into preexisting ducts.

CONCLUSION: DAP are neoplasms of prostatic origin, and the terms endometrioid or endometrial adenocarcinoma are best avoided.

DAP are aggressive tumors with a shortened average time to progression compared with acinar adenocarcinoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18773743.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 36

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation.

BACKGROUND AND PURPOSE: Cyclooxygenase-2 (COX-2) is expressed in colonic neoplasms, where it supports cell proliferation via prostaglandin E(2) (PGE(2)) production.

EXPERIMENTAL APPROACH: Human colon adenocarcinoma cell lines Caco-2, HT-29 and HCT116 were used.

The following techniques were employed: colourimetric assay for cell growth; 5-bromo-2'-deoxyuridine assay for DNA synthesis; enzyme immunoassay for PGE(2); COX-2 mRNA silencing; RT-PCR or Western blot for somatostatin receptor subtypes, cyclooxygenase isoforms, phosphorylated-ERK-1/ERK-2 and phosphorylated-Akt.

Somatostatin-14 inhibited basal COX-2 expression, PGE(2) production, DNA synthesis and growth in Caco-2 cells and these effects were prevented by BN81658 (sst(3) receptor antagonist).

Basal proliferation of HT-29, HCT116 and COX-2-silenced Caco-2 cells was not affected by somatostatin-14.

Stimulation of HT-29 cells with gastrin-17 elicited increments of ERK-1/ERK-2 and Akt phosphorylation, COX-2 expression, PGE(2) production, DNA synthesis and cell growth, which were all counteracted by somatostatin-14.

CONCLUSIONS AND IMPLICATIONS: Somatostatin decreases COX-2 expression and function in colon cancer cells via activation of sst(3) or sst(5) receptors, and these effects contribute to the inhibitory action of somatostatin on cell proliferation.

[MeSH-major] Cell Proliferation / drug effects. Colonic Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Cyclooxygenase 2 Inhibitors / pharmacology. Somatostatin / pharmacology

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Colorectal Dis. 2001 Aug;16(4):202-10 [11515678.001]

[Cites] Science. 1998 Oct 23;282(5389):737-40 [9784130.001]

[Cites] Eur J Endocrinol. 1999 Apr;140(4):362-6 [10097257.001]

[Cites] Cancer Biol Ther. 2004 Aug;3(8):726-30 [15197339.001]

[Cites] Br J Pharmacol. 2005 Feb;144(3):338-48 [15655524.001]

[Cites] N Engl J Med. 2005 Mar 17;352(11):1092-102 [15713943.001]

[Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]

[Cites] J Clin Oncol. 2005 Jul 10;23(20):4553-60 [16002847.001]

[Cites] Oncology. 2005;69 Suppl 1:28-32 [16210874.001]

[Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]

[Cites] Int J Oncol. 2006 Feb;28(2):543-9 [16391811.001]

[Cites] World J Gastroenterol. 2006 Apr 7;12(13):2011-5 [16610049.001]

[Cites] Cancer Res. 2006 Oct 1;66(19):9705-13 [17018629.001]

[Cites] N Engl J Med. 2007 May 24;356(21):2131-42 [17522398.001]

[Cites] Br J Pharmacol. 2008 Mar;153 Suppl 2:S1-209 [18347570.001]

[Cites] Mol Endocrinol. 2001 Oct;15(10):1838-52 [11579215.001]

[Cites] Eur J Clin Invest. 2001 Sep;31(9):812-20 [11589724.001]

[Cites] Gastroenterology. 2001 Oct;121(4):915-30 [11606505.001]

[Cites] J Mol Neurosci. 2002 Feb-Apr;18(1-2):15-27 [11931345.001]

[Cites] J Biol Chem. 2003 Feb 28;278(9):6992-7000 [12493747.001]

[Cites] Endocrinology. 2003 Apr;144(4):1574-84 [12639942.001]

[Cites] Carcinogenesis. 2003 Apr;24(4):637-42 [12727790.001]

[Cites] Biochim Biophys Acta. 2003 Sep 22;1616(1):1-84 [14507421.001]

[Cites] Nat Rev Drug Discov. 2003 Dec;2(12):999-1017 [14654798.001]

[Cites] Pharmacol Ther. 2004 Apr;102(1):61-85 [15056499.001]

[Cites] Biochem Pharmacol. 2004 Sep 15;68(6):1089-100 [15313405.001]

[Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]

[Cites] Cancer Res. 1992 Feb 15;52(4):917-23 [1737355.001]

[Cites] Life Sci. 1993;53(1):85-90 [8515684.001]

[Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):844-52 [8373420.001]

[Cites] J Mol Endocrinol. 2000 Jun;24(3):397-408 [10828833.001]

[Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]

[Cites] J Clin Endocrinol Metab. 2001 May;86(5):2161-9 [11344221.001]

[Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4 [7878022.001]

[Cites] Cancer. 1995 Sep 15;76(6):961-6 [8625221.001]

[Cites] Biochem J. 1996 Mar 1;314 ( Pt 2):401-4 [8670047.001]

[Cites] Br J Pharmacol. 1996 Jun;118(3):445-7 [8762063.001]

[Cites] Br J Cancer. 1997;75(3):360-6 [9020480.001]

[Cites] Am J Physiol. 1997 May;272(5 Pt 1):E769-74 [9176174.001]

[Cites] Mol Endocrinol. 1997 Jul;11(8):1062-9 [9212054.001]

[Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9343-8 [9256484.001]

[Cites] Life Sci. 1997;61(10):1009-18 [9296339.001]

[Cites] Gastroenterology. 1998 Aug;115(2):275-80 [9679032.001]

[Cites] Diabetes. 1999 Jan;48(1):77-85 [9892225.001]

(PMID = 18587421.001).

[ISSN] 0007-1188

[Journal-full-title] British journal of pharmacology

[ISO-abbreviation] Br. J. Pharmacol.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / BIM 23056; 0 / Cyclooxygenase 2 Inhibitors; 0 / Gastrins; 0 / Oligopeptides; 51110-01-1 / Somatostatin; 60748-06-3 / gastrin 17; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases

[Other-IDs] NLM/ PMC2538699

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

We highlight the differential diagnosis, particularly sebaceous carcinoma and basal cell carcinoma with sebaceous differentiation.

[MeSH-major] Ear Canal / pathology. Sebaceous Gland Neoplasms / pathology

[MeSH-minor] Adenocarcinoma, Sebaceous / pathology. Aged. Carcinoma, Basal Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18564279.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells.

Periostin is a secretory protein that has been suggested to function as a cell adhesion molecule and promote the invasiveness or growth rate of tumors.

However, little is known about the association of its expression and epithelial to mesenchymal transition (EMT), which is considered to play a crucial role in cancer cell metastasis.

In vitro, pancreatic stellate cells (PSCs) exhibited a much higher basal expression of periostin compared with cancer cells.

To assess the direct role of periostin in pancreatic cancer cells, the authors generated pancreatic cancer cell lines that stably express periostin.

The induced expression of periostin (to 150 ng/ml) altered the morphology of cancer cells, changing them from mesenchymal to epithelial phenotypes with the induction of epithelial markers and a reduction of mesenchymal markers, and showed reduced cell migration in vitro and formed smaller tumors as well as suppressed metastasis in vivo.

On the other hand, high concentration of recombinant periostin (1 microg/ml) promoted cell migration with AKT activation.

[MeSH-major] Adenocarcinoma / pathology. Cell Adhesion Molecules / physiology. Cell Movement / physiology. Epithelium / pathology. Mesoderm / physiology. Pancreatic Neoplasms / pathology

[MeSH-minor] Animals. Base Sequence. Cell Line, Tumor. Coculture Techniques. DNA Primers. Humans. Mice. Rats. Reverse Transcriptase Polymerase Chain Reaction

Genetic Alliance. consumer health - Pancreatic cancer.

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

COS Scholar Universe. author profiles.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] (c) 2008 Wiley-Liss, Inc.

(PMID = 18381746.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / POSTN protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.

Distinguishing adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma of the salivary glands is important for their management.

We studied the expression of several myoepithelial and basal/stem cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, metallothionein, maspin, and p63) by immunohistochemistry in 23 adenoid cystic carcinoma and 24 polymorphous low-grade adenocarcinoma, to identify the most useful marker or combination of markers that may help their diagnoses.

We noted diffuse expression of smooth muscle actin in 20 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), calponin in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P<0.0001), smooth muscle myosin heavy chain in 15 adenoid cystic carcinoma vs one polymorphous low-grade adenocarcinoma (P=0.001), metallothionein in 22 adenoid cystic carcinoma vs eight polymorphous low-grade adenocarcinoma (P<0.001), maspin in 22 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma, and p63 in 21 adenoid cystic carcinoma vs 14 polymorphous low-grade adenocarcinoma.

In differentiating adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma, smooth muscle actin as a single ancillary test in support of the histological findings, appears to be as efficient as multiple immunohistochemical tests.

[MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Epithelial Cells / metabolism. Myocytes, Smooth Muscle / metabolism. Neoplasm Proteins / metabolism. Salivary Gland Neoplasms / metabolism

[MeSH-minor] Adult. Aged. Aged, 80 and over. Cluster Analysis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Salivary Glands, Minor / metabolism. Salivary Glands, Minor / pathology. Treatment Outcome

Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

Genetic Alliance. consumer health - Myoepithelial carcinoma.

Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18084258.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Koumine-induced apoptosis of human colonic adenocarcinoma cells: the cell biological mechanism].

OBJECTIVE: To investigate the cell biological mechanism of koumine-induced apoptosis of human colonic adenocarcinoma cells.

METHODS: The effects of LoVo cell koumine on the membrane potential, mitochondrial membrane potential, concentration of cytosolic free calcium, reactive oxygen species (ROS) and gap junctional intercellular communication was observed by laser scanning confocal microscopy.

RESULTS AND CONCLUSION: Koumine lowered the membrane potential and mitochondrial membrane potential of LoVo cells and decreased the concentration of free cytosolic calcium, which was increased to a level higher than the basal one after addition of EDTA.

These findings may explain the possible mechanisms of koumine-induced LoVo cell apoptosis.

[MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Colonic Neoplasms / pathology. Indole Alkaloids / pharmacology

[MeSH-minor] Calcium / metabolism. Cell Communication / drug effects. Cell Line, Tumor. Gap Junctions / drug effects. Gap Junctions / metabolism. Humans. Membrane Potential, Mitochondrial / drug effects. Microscopy, Confocal. Reactive Oxygen Species / metabolism

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17666335.001).

[ISSN] 1673-4254

[Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

[Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indole Alkaloids; 0 / Reactive Oxygen Species; 0 / koumine; SY7Q814VUP / Calcium

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.

Typically glands of prostatic adenocarcinoma have a single cell lining, although stratification can be seen in invasive carcinomas with a cribriform architecture, including ductal carcinoma.

The histomorphological features and immunohistochemical profile of cases of non-cribriform prostatic adenocarcinoma with stratified malignant glandular epithelium were analyzed.

These cases were identified from needle biopsy cases from the consultation files of one of the authors and from a review of 150 consecutive in-house needle biopsy cases of prostatic adenocarcinoma.

The main attribute in all these foci was the presence of glandular profiles lined by several layers of epithelial cells with cytological and architectural features resembling flat or tufted high-grade prostatic intraepithelial neoplasia, but lacking basal cells as confirmed by negative 34betaE12 and/or p63 immunostains in all cases.

The AMACR staining profile of the stratified foci was variable, with 4 foci showing positivity, and 3 foci being negative, including two cases that displayed AMACR positivity in adjacent non-stratified prostatic adenocarcinoma.

Prostatic adenocarcinoma with stratified malignant glandular epithelium can be identified in prostate needle biopsy samples harboring non-cribriform prostatic adenocarcinoma and resembles glands with high-grade prostatic intraepithelial neoplasia.

Recognition of this pattern of prostatic adenocarcinoma is necessary to correctly diagnose such cases as invasive carcinoma.

[MeSH-major] Adenocarcinoma / pathology. Epithelium / pathology. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Neoplasms / pathology

[MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Membrane Proteins / metabolism. Middle Aged. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Racemases and Epimerases / metabolism. Retrospective Studies

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16607376.001).

[ISSN] 0893-3952

[Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

[ISO-abbreviation] Mod. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Membrane Proteins; 68238-35-7 / Keratins; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Peripheral myelin protein 22 is in complex with alpha6beta4 integrin, and its absence alters the Schwann cell basal lamina.

In the absence of PMP22, myelination of peripheral nerves is delayed, and numerous axon-SC profiles show loose basal lamina, suggesting altered interactions of the glial cells with the extracellular matrix.

The levels of beta4 integrin, a molecule involved in the linkage between SCs and the basal lamina, are severely reduced in nerves of PMP22-deficient mice.

During early stages of myelination, PMP22 and beta4 integrin are coexpressed at the cell surface and can be coimmunoprecipitated together with laminin and alpha6 integrin.

[MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Animals. Basement Membrane / metabolism. Basement Membrane / ultrastructure. Binding Sites. Cell Line, Tumor / chemistry. Coculture Techniques. Colonic Neoplasms / chemistry. Colonic Neoplasms / pathology. Exons / genetics. Ganglia, Spinal / cytology. Humans. Lac Operon. Laminin / metabolism. Mice. Mice, Knockout. Mice, Transgenic. Multiprotein Complexes. Organ Specificity. Peripheral Nervous System Diseases / genetics. Peripheral Nervous System Diseases / metabolism. Peripheral Nervous System Diseases / pathology. Phenotype. Protein Binding. Protein Interaction Mapping. Rats. Sciatic Nerve / metabolism. Sciatic Nerve / ultrastructure

COS Scholar Universe. author profiles.

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

SciCrunch. Marmoset Gene list: Data: Gene Annotation .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16436605.001).

[ISSN] 1529-2401

[Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience

[ISO-abbreviation] J. Neurosci.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Integrin alpha6beta4; 0 / Laminin; 0 / Multiprotein Complexes; 0 / Myelin Proteins; 0 / PMP22 protein, human; 0 / Pmp22 protein, mouse; 0 / Pmp22 protein, rat

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Differences in the structural features of atypical adenomatous hyperplasia and low-grade prostatic adenocarcinoma.

AIM: Atypical adenomatous hyperplasia (AAH) is a small glandular proliferation that has histological similarities with Gleason grade 1 and 2 prostatic adenocarcinoma (PACG1,2).

Basal cell-specific antikeratin was applied to these lesions.

We assumed that PACG1,2 lesions did have not basal cells and we grouped the lesions as AAH and PACG1,2 based on this assumption.

RESULTS: We found differences between AAH and PACG1,2 lesions for some parameters including the number of glands, structures such as the main ductus and basal cells.

We found similar properties in the two lesions for the following parameters: localization, multiplicity, diameter of the lesion, focus asymmetry, distance between glands, inflammatory cells in and out of the lesions, secretory cell shape on the luminal side, papillary projection towards the luminal side of gland, the shape of the outer gland, the infiltrative pattern of the gland, glandular pleomorphism, biggest gland diameter and median gland diameter.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Urology. 1995 Dec;46(6):837-42 [7502426.001]

[Cites] Hum Pathol. 1996 Apr;27(4):396-407 [8617484.001]

[Cites] Am J Surg Pathol. 1995 Jul;19(7):737-47 [7793471.001]

[Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6 [1696762.001]

[Cites] Indian J Cancer. 2004 Apr-Jun;41(2):60-5 [15318010.001]

[Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]

[Cites] Am J Surg Pathol. 2002 Jul;26(7):921-5 [12131160.001]

[Cites] Ann N Y Acad Sci. 2002 Jun;963:169-84 [12095942.001]

[Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]

[Cites] Anal Quant Cytol Histol. 2000 Dec;22(6):438-44 [11147297.001]

[Cites] Pathol Res Pract. 1999;195(12):795-9 [10631713.001]

[Cites] Br J Cancer. 1994 Jun;69(6):1098-101 [7515262.001]

[Cites] Am J Surg Pathol. 1994 Sep;18(9):863-70 [7520673.001]

[Cites] Hum Pathol. 1993 Jun;24(6):618-23 [7684998.001]

[Cites] Hum Pathol. 1993 Aug;24(8):819-32 [8375853.001]

[Cites] Hum Pathol. 1992 Mar;23(3):273-9 [1555838.001]

[Cites] Mod Pathol. 1991 Mar;4(2):220-4 [1710806.001]

[Cites] Cancer. 1987 Feb 15;59(4):788-94 [2433020.001]

[Cites] J Clin Pathol. 1989 Apr;42(4):383-6 [2469700.001]

[Cites] J Postgrad Med. 1989 Jul;35(3):157-61 [2483935.001]

[Cites] Am J Surg Pathol. 1988 Dec;12(12):897-906 [3202246.001]

[Cites] Am J Surg Pathol. 1985 Jan;9(1):53-5 [3970298.001]

[Cites] Nat Clin Pract Urol. 2007 Jun;4(6):321-32 [17551536.001]

[Cites] Crit Rev Clin Lab Sci. 2007;44(3):243-70 [17453919.001]

[Cites] Asian J Androl. 2007 Mar;9(2):229-33 [16751999.001]

[Cites] Ann Saudi Med. 1998 Jan-Feb;18(1):22-7 [17341910.001]

[Cites] Int J Surg Pathol. 2005 Apr;13(2):167-73 [15864380.001]

[Cites] Hum Pathol. 1999 Sep;30(9):1077-86 [10492043.001]

[Cites] Am J Pathol. 1999 Sep;155(3):967-71 [10487854.001]

[Cites] Mod Pathol. 1999 May;12(5):472-8 [10349984.001]

[Cites] Mod Pathol. 1999 May;12(5):443-4 [10349979.001]

[Cites] Am J Surg Pathol. 1999 Feb;23(2):147-52 [9989840.001]

[Cites] Urology. 1999 Feb;53(2):351-5 [9933053.001]

[Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):417-23 [9801760.001]

[Cites] Cancer Res. 1998 Feb 1;58(3):389-91 [9458077.001]

[Cites] Am J Clin Pathol. 1997 Feb;107(2):219-23 [9024071.001]

[Cites] Pathologica. 1997 Jun;89(3):288-300 [9270265.001]

[Cites] Cancer. 1997 Mar 15;79(6):1172-9 [9070495.001]

[Cites] Mod Pathol. 1996 Jan;9(1):77-81 [8821962.001]

[Cites] Cancer. 1996 Jul 15;78(2):330-6 [8674012.001]

[Cites] Am J Surg Pathol. 1995 May;19(5):506-18 [7537024.001]

(PMID = 19468392.001).

[ISSN] 0970-1591

[Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India

[ISO-abbreviation] Indian J Urol

[Language] eng

[Publication-type] Journal Article

[Publication-country] India

[Other-IDs] NLM/ PMC2684265

[Keywords] NOTNLM ; Adenosis / cancer / hyperplasia / low grade / proliferations / prostate / small glandular

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basal cell carcinoma of the prostate: report of a case and review of the published reports.

Prostatic basal cell carcinoma (BCC), a distinctive variant of adenocarcinoma, is rare.

[MeSH-major] Carcinoma, Basal Cell. Prostatic Neoplasms

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18489650.001).

[ISSN] 1442-2042

[Journal-full-title] International journal of urology : official journal of the Japanese Urological Association

[ISO-abbreviation] Int. J. Urol.

[Language] eng

[Publication-type] Case Reports; Journal Article; Review

[Publication-country] Australia

[Number-of-references] 10

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas.

Basal-like tumors are a newly recognized estrogen receptor (ER) negative and HER2 negative breast cancer subtype that express basal epithelial genes and are associated with poor survival.

Metaplastic carcinomas are thought to belong within the basal-like group.

We have recently demonstrated that the small heat shock protein alphaB-crystallin is commonly expressed in basal-like tumors and contributes to their aggressive phenotype.

The current study examined the rates and patterns of alphaB-crystallin expression in whole tissue sections of human breast, including normal tissue, proliferative lesions, in situ and invasive carcinomas (ER positive, HER2 positive, basal-like, and metaplastic cancers).

In normal breast tissue, proliferative lesions and in situ carcinomas, alphaB-crystallin expression was restricted to the myoepithelial cell compartment of ductal and lobular units.

Most basal-like and metaplastic carcinomas demonstrated cytoplasmic expression of alphaB-crystallin (81% and 86%, respectively).

Taken together, our results indicate that alphaB-crystallin is a sensitive (81%) and specific (100%) marker for basal-like breast carcinomas.

Moreover, the high rates of expression of alphaB-crystallin in metaplastic breast carcinomas (86%) suggest that these tumors may represent a histologically distinctive subset of basal-like breast tumors with a similar underlying molecular etiology.

[MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. alpha-Crystallin B Chain / metabolism

[MeSH-minor] Breast Cyst / metabolism. Breast Cyst / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Proliferation. Female. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Metaplasia. Neoplasm Invasiveness. Predictive Value of Tests

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18164413.001).

[ISSN] 1092-9134

[Journal-full-title] Annals of diagnostic pathology

[ISO-abbreviation] Ann Diagn Pathol

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P50CA89018; United States / NCI NIH HHS / CA / R01CA097198

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / alpha-Crystallin B Chain

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma.

The 2004 WHO classification of lung tumours recognised basaloid carcinoma as a variant of squamous and large cell carcinoma.

We report a unique case of primary pulmonary adenocarcinoma with a basaloid component.

The patient is disease-free 13 months after diagnosis.

The former was an adenocarcinoma with mucus containing spaces lined by columnar mucinous cells and basaloid cells.

The solid component was an organoid proliferation of basaloid-type cells, as in cutaneous basal cell carcinoma.

(1) The solid areas resemble a conventional basaloid carcinoma, except for the presence of small mucin-containing spaces. (2) The mucinous adenocarcinoma areas contain two layers of columnar and basaloid cells. (3) Both components are neoplastic based on cell morphology, invasive properties and phenotypic profile.

These findings indicate that a basaloid variant of adenocarcinoma is also existing in the spectrum of basaloid carcinomas of the lung.

[MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

[MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell. Humans. Keratins / analysis. Male. Mucins / analysis. Neoplasm Invasiveness. Phenotype. World Health Organization

MedlinePlus Health Information. consumer health - Lung Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]

[Cites] Pathol Res Pract. 2005;201(10):705-11 [16325513.001]

[Cites] Am J Surg Pathol. 2004 Apr;28(4):442-52 [15087663.001]

[Cites] Am J Surg Pathol. 2005 Dec;29(12 ):1668-72 [16327441.001]

[Cites] Hum Pathol. 1992 Sep;23(9):993-1003 [1381335.001]

[Cites] Am J Dermatopathol. 2003 Feb;25(1):77-80 [12544106.001]

[Cites] Diagn Pathol. 2006 Aug 15;1:19 [16911776.001]

[Cites] HNO. 1998 Sep;46(9):821-5 [9816537.001]

[Cites] J Thorac Oncol. 2015 Sep;10 (9):1240-1242 [26291007.001]

[Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1124-30 [15387711.001]

[Cites] Am J Surg Pathol. 2003 Dec;27(12):1523-9 [14657711.001]

[Cites] Mod Pathol. 2005 May;18(5):645-50 [15529180.001]

[Cites] Am J Clin Pathol. 2006 Jun;125(6):847-54 [16690483.001]

[Cites] Pathol Int. 2005 Jul;55(7):445-52 [15982222.001]

[Cites] Pathol Res Pract. 2006;202(6):475-80 [16487667.001]

[Cites] Am J Surg Pathol. 2004 Oct;28(10):1289-98 [15371944.001]

[Cites] Virchows Arch. 2005 Mar;446(3):338-41 [15726402.001]

(PMID = 17618455.001).

[ISSN] 0945-6317

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Mucins; 68238-35-7 / Keratins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

RESULTS: Six Men1+/- mice (12.8%) developed prostate cancer, including two adenocarcinomas and four in situ carcinomas, while none of the control mice developed cancerous lesions.

Using immunostaining for the androgen receptor and p63, a basal epithelial cell marker, we demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in these lesions.

Furthermore, our data showed that the expression of the cyclin-dependent kinase inhibitor CDKN1B (p27), a Men1 target gene known to be inactivated during prostate cell tumorigenesis, was notably decreased in the prostate cancers that developed in the mutant mice.

CONCLUSION: Our work suggests the possible involvement of Men1 inactivation in the tumorigenesis of the prostate gland.

[MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Loss of Heterozygosity. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. Proto-Oncogene Proteins / physiology

MedlinePlus Health Information. consumer health - Prostate Cancer.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Mol Cell Biol. 2000 Aug;20(16):6147-58 [10913196.001]

[Cites] Breast Cancer Res Treat. 2010 Jul;122(2):395-407 [19847644.001]

[Cites] Nat Genet. 2001 Feb;27(2):222-4 [11175795.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1118-23 [11158604.001]

[Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]

[Cites] J Biol Chem. 2002 Nov 15;277(46):43749-56 [12226080.001]

[Cites] Mod Pathol. 2002 Dec;15(12):1302-8 [12481011.001]

[Cites] J Clin Endocrinol Metab. 2003 Mar;88(3):1333-40 [12629127.001]

[Cites] Mech Dev. 2003 May;120(5):549-60 [12782272.001]

[Cites] J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82 [12843129.001]

[Cites] Mol Endocrinol. 2003 Sep;17(9):1880-92 [12819299.001]

[Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]

[Cites] PLoS Biol. 2003 Dec;1(3):E59 [14691534.001]

[Cites] Nature. 1992 Nov 26;360(6402):313-9 [1448148.001]

[Cites] Cell. 1994 Nov 4;79(3):415-25 [7954809.001]

[Cites] Mol Endocrinol. 1995 Oct;9(10):1337-45 [8544842.001]

[Cites] Genes Dev. 1996 Oct 15;10(20):2577-87 [8895659.001]

[Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2617-20 [9709920.001]

[Cites] J Invest Dermatol. 1998 Sep;111(3):539-40 [9740255.001]

[Cites] Med Klin (Munich). 1998 Sep 15;93(9):546-9 [9792021.001]

[Cites] Genes Dev. 1999 Apr 15;13(8):966-77 [10215624.001]

[Cites] Cancer Metastasis Rev. 1998-1999;17(4):337-44 [10453277.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17204-9 [15569926.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 [15640349.001]

[Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14659-64 [16195383.001]

[Cites] Cancer Res. 2006 Feb 15;66(4):2188-94 [16489020.001]

[Cites] Fam Cancer. 2006;5(1):49-54 [16528608.001]

[Cites] Cancer Res. 2006 May 1;66(9):4929-35 [16651450.001]

[Cites] Cancer Res. 2006 Aug 1;66(15):7783-92 [16885382.001]

[Cites] Int J Cancer. 2007 Jan 15;120(2):259-67 [17044021.001]

[Cites] Eur J Cancer. 2007 Jan;43(2):402-14 [17184987.001]

[Cites] Mol Cell Endocrinol. 2007 Feb;265-266:34-41 [17222504.001]

[Cites] Nat Genet. 2008 Mar;40(3):310-5 [18264096.001]

[Cites] Endocr Relat Cancer. 2008 Mar;15(1):217-27 [18310289.001]

[Cites] Cancer Res. 2008 Aug 1;68(15):6396-406 [18676865.001]

[Cites] J Endocrinol. 2008 Dec;199(3):489-97 [18827067.001]

[Cites] Dev Biol. 2008 Dec 15;324(2):310-9 [18950615.001]

[Cites] Prostate Cancer Prostatic Dis. 2009;12(2):184-91 [18779856.001]

[Cites] Mol Cell Biol. 2009 Sep;29(18):5060-9 [19596783.001]

[Cites] Cancer Res. 2000 Nov 1;60(21):6111-5 [11085535.001]

(PMID = 20663219.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Men1 protein, mouse; 0 / Phosphoproteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Androgen; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27

[Other-IDs] NLM/ PMC2920881

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Role of CDK8 and beta-catenin in colorectal adenocarcinoma.

Colorectal adenocarcinoma is a major cause of morbidity and mortality.

CDK8 is a cyclin-dependent kinase (CDK) member of the mediator complex that couples transcriptional regulators to the basal transcriptional machinery, and is implicated in the transcriptional regulation of key pathways involved in colon cancers.

To determine the relationship between CDK8 and beta-catenin expressions, a population-based study was conducted for immunohistochemical staining analysis of tumor tissues, and Western blot analysis and CDK8 interference studies of colon cancer cell lines.

However, beta-catenin expression was not completely suppressed by CDK8 interference in the colon cancer cell lines HCT-116, HT-29 and SNU-C5.

[MeSH-major] Adenocarcinoma / metabolism. Colorectal Neoplasms / metabolism. Cyclin-Dependent Kinase 8 / physiology. beta Catenin / physiology

MedlinePlus Health Information. consumer health - Colorectal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20514474.001).

[ISSN] 1791-2431

[Journal-full-title] Oncology reports

[ISO-abbreviation] Oncol. Rep.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Greece

[Chemical-registry-number] 0 / RNA, Small Interfering; 0 / beta Catenin; EC 2.7.11.22 / CDK8 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 8

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Barrett's oesophagus is a metaplastic pre-malignant disorder and the only established precursor lesion for oesophageal adenocarcinoma.

These stem cells could be located in the basal layer of the squamous oesophageal epithelium and/or in the neck region of the oesophageal submucosal gland ducts; however, their exact location and identification are still matter of discussion.

[MeSH-minor] Animals. Cell Movement / physiology. Cell Transdifferentiation / physiology. Epithelial Cells / cytology. Epithelial Cells / physiology. Gastric Mucosa / cytology. Gastric Mucosa / pathology. Gastric Mucosa / physiology. Humans. Metaplasia / pathology

MedlinePlus Health Information. consumer health - Stem Cells.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20298185.001).

[ISSN] 1470-8752

[Journal-full-title] Biochemical Society transactions

[ISO-abbreviation] Biochem. Soc. Trans.

[Language] eng

[Grant] United Kingdom / Medical Research Council / / MC/ U105365007; United Kingdom / Medical Research Council / /

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] England

[Number-of-references] 36

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Features included cells with frequent organoid, nested or cord-like arrangement (8), lumen formation (2; one of which showed surface microvilli), nuclei with irregular indentations (8), intermediate filaments (13), prominent paranuclear aggregates (5), cell junctions (9), desmosome-like junctions (2), tonofilaments (2), basal lamina (1), and cytoplasmic lipid droplets (7; prominent in 3).

[MeSH-major] Adenocarcinoma / diagnosis. Ovarian Neoplasms / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Uterine Neoplasms / diagnosis

[MeSH-minor] Biomarkers, Tumor / analysis. Calbindin 2. Cell Nucleus / ultrastructure. Cytoplasmic Structures / ultrastructure. Desmosomes / ultrastructure. Diagnosis, Differential. Female. Humans. Intermediate Filaments / ultrastructure. Keratins / analysis. Microscopy, Electron, Transmission. S100 Calcium Binding Protein G / analysis

MedlinePlus Health Information. consumer health - Ovarian Cancer.

MedlinePlus Health Information. consumer health - Uterine Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20070149.001).

[ISSN] 1521-0758

[Journal-full-title] Ultrastructural pathology

[ISO-abbreviation] Ultrastruct Pathol

[Language] eng

[Publication-type] Journal Article

[Publication-country] England

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The study comprised 29,926 skin cancer cases (excluding basal cell and squamous cell carcinomas) and 119,704 controls, frequency-matched by gender, age and calendar year (1987-2002).

Medicare claims identified solid-organ transplantation or HIV infection before cancer diagnosis/control selection.

Solid-organ transplantation was also associated with increased risks of Merkel cell carcinoma (N = 1,286; OR [95%CI] 4.95 [2.62-9.34]) and other cutaneous sarcomas (N = 972; 4.19 [1.83-9.56]).

[MeSH-major] Adenocarcinoma / etiology. HIV Infections / complications. HIV Infections / therapy. HIV-1 / pathogenicity. Organ Transplantation / adverse effects. Skin Neoplasms / etiology

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

MedlinePlus Health Information. consumer health - Organ Transplantation.

MedlinePlus Health Information. consumer health - Skin Cancer.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Transplantation. 1999 Dec 15;68(11):1717-21 [10609948.001]

[Cites] AIDS. 2009 Jan 28;23(3):385-93 [19114864.001]

[Cites] Ophthal Plast Reconstr Surg. 2000 May;16(3):206-10 [10826761.001]

[Cites] J Invest Dermatol. 2001 Feb;116(2):246-53 [11180000.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):371-6 [11317081.001]

[Cites] Dermatol Surg. 2001 Nov;27(11):955-9 [11737130.001]

[Cites] Eur J Med Res. 2002 Mar 28;7(3):135-7 [11953286.001]

[Cites] Arch Dermatol. 2002 Jun;138(6):758-63 [12056956.001]

[Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]

[Cites] J Am Acad Dermatol. 2003 Mar;48(3):401-8 [12637920.001]

[Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]

[Cites] Transplantation. 2004 Feb 27;77(4):574-9 [15084938.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):861-8 [15213571.001]

[Cites] Natl Cancer Inst Monogr. 1976 Nov;44:67-76 [799762.001]

[Cites] Arch Dermatol. 1988 Apr;124(4):489-90 [3355190.001]

[Cites] AIDS. 1990 Jan;4(1):91 [2317312.001]

[Cites] Clin Exp Dermatol. 1991 Mar;16(2):131-2 [2032376.001]

[Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]

[Cites] Can J Ophthalmol. 1995 Oct;30(6):324-6 [8574982.001]

[Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]

[Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]

[Cites] JAMA. 2006 Dec 20;296(23):2823-31 [17179459.001]

[Cites] Am J Transplant. 2007 Feb;7(2):476-9 [17229076.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] Science. 2008 Feb 22;319(5866):1096-100 [18202256.001]

[Cites] J Natl Cancer Inst. 2008 May 7;100(9):630-41 [18445825.001]

[Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]

[Cites] Cancer. 2008 Aug 1;113(3):616-27 [18618615.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3069-75 [18957521.001]

[Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]

(PMID = 19810102.001).

[ISSN] 1097-0215

[Journal-full-title] International journal of cancer

[ISO-abbreviation] Int. J. Cancer

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP010150-08

[Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural

[Publication-country] United States

[Other-IDs] NLM/ NIHMS146606; NLM/ PMC2818159

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Mucinous, tubular, or secretary carcinomas were frequently found in the hormone receptor positive/HER2 negative subtype, while squamous cell carcinoma, spindle cell carcinoma, and metaplastic carcinoma with bone/cartilage metaplasia were very frequently found in the TN group.

CONCLUSIONS: Although TN types are similar to basal-like breast tumor, as determined by gene profiling, their diagnosis needs verification by determination of the level of epidermal growth factor receptor or cytokeratin 5/6 expression.

[MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Female. Humans. Japan. Middle Aged. Prognosis. Receptor, ErbB-2 / metabolism. Registries. Societies, Medical / statistics & numerical data. Young Adult

Genetic Alliance. consumer health - Breast Cancer.

Genetic Alliance. consumer health - Triple Negative Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19466512.001).

[ISSN] 1880-4233

[Journal-full-title] Breast cancer (Tokyo, Japan)

[ISO-abbreviation] Breast Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Japan

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Ten patients underwent transthoracic esophagectomy because of submucosal infiltration combined incomplete tumor resection at the lateral/basal resection margin.

RESULTS: Three patients had a squamous cell carcinoma (SCC) and 13 patients an adenocarcinoma (AC), nine patients with a long segment Barrett's esophagus.

MedlinePlus Health Information. consumer health - Endoscopy.

MedlinePlus Health Information. consumer health - Esophageal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Thorac Surg. 2004 Oct;78(4):1177-83 [15464466.001]

[Cites] Langenbecks Arch Surg. 2006 Sep;391(5):455-60 [16896830.001]

[Cites] Ann Surg. 2000 Dec;232(6):733-42 [11088068.001]

[Cites] Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4 [15570202.001]

[Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]

[Cites] AJR Am J Roentgenol. 1999 Aug;173(2):365-7 [10430138.001]

[Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]

[Cites] Jpn J Surg. 1976 Jun;6(2):69-78 [994356.001]

[Cites] Virchows Arch. 2005 May;446(5):497-504 [15838647.001]

[Cites] Langenbecks Arch Surg. 2006 Aug;391(4):304-21 [16830151.001]

[Cites] Am J Surg Pathol. 2006 Jan;30(1):114-8 [16330950.001]

[Cites] Ann Surg Oncol. 2002 Oct;9(8):807-11 [12374665.001]

[Cites] Dis Esophagus. 2000;13(2):125-9 [14601903.001]

[Cites] Can J Gastroenterol. 1998 Jul-Aug;12(5):355-9 [9773215.001]

[Cites] Gut. 2001 Oct;49(4):534-9 [11559651.001]

[Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]

[Cites] Chirurg. 2003 Aug;74(8):726-33 [12928793.001]

[Cites] Br J Surg. 1997 Oct;84(10):1470-3 [9361616.001]

[Cites] Gut. 2004 May;53(5):634-40 [15082579.001]

[Cites] Cancer. 1995 Jul 15;76(2):178-86 [8625089.001]

[Cites] Endoscopy. 2004 Sep;36(9):776-81 [15326572.001]

[Cites] Endoscopy. 2007 Jan;39(1):77-9 [17323470.001]

[Cites] Am J Gastroenterol. 2004 Jul;99(7):1226-32 [15233658.001]

[Cites] Endoscopy. 2006 Feb;38(2):149-56 [16479422.001]

[Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]

[Cites] Ann Surg. 2004 Nov;240(5):791-800 [15492560.001]

[Cites] World J Surg. 2002 May;26(5):584-7 [12098049.001]

[Cites] Ann Surg. 2004 Apr;239(4):483-90 [15024309.001]

[Cites] Ann Surg. 2007 Feb;245(2):241-6 [17245177.001]

(PMID = 18923875.001).

[ISSN] 1873-4626

[Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

[ISO-abbreviation] J. Gastrointest. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The 5 leading eyelid malignant tumors were basal cell carcinoma, sebaceous gland carcinoma, lymphoma, squamous cell carcinoma and melanoma.

The mean age at diagnosis was 61 years for basal cell carcinoma and sebaceous gland carcinoma, 57 years and 52 years for squamous cell carcinoma and melanoma, respectively, and 48 years for lymphoma.

There was no significant sex predilection in basal cell carcinoma and sebaceous gland carcinoma.

Melanoma and lymphoma occurred more commonly in women, whereas squamous cell carcinoma occurred more commonly in men.

CONCLUSIONS: Basal cell carcinoma and sebaceous gland carcinoma were the most common malignant eyelid tumors, and lymphoma ranked third and had an increasing trend.

[MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Lymphoma / pathology

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18510241.001).

[ISSN] 0412-4081

[Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology

[ISO-abbreviation] Zhonghua Yan Ke Za Zhi

[Language] chi

[Publication-type] English Abstract; Journal Article

[Publication-country] China

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study.

The morphologic features of the 278 cases and immunohistochemistry of 236 cases (198 with prostate cocktail and 38 with only basal cell makers) were analyzed.

Of 198 cases with a prostatic cocktail stain, 48 (24.2%) had a cancer pattern for both basal cells and AMACR (p63-, HMWCK-, and AMACR+), 14 (7.1%) had a cancer pattern for basal cells (p63-, HMWCK-, and AMACR-), 89 (44.9%) had a cancer pattern for AMACR (p63+, HMWCK+, and AMACR+), and 47 (23.7%) had a totally benign pattern (p63+, HMWCK+, and AMACR-).

Of the 198 cases using the cocktail stain, 136 (68.7%) had positive basal cell staining.

The percentage of basal cells labeled with the combination of p63/HMWCK was: <5% in 42 (21.2%) cases, 5% to 75% in 58 (29.3%) cases, and >75% in 36 (18.2%) cases.

In conclusion, partial atrophy is a benign mimicker of adenocarcinoma both as a result of its routine morphologic features and its immunohistochemical profile.

Recognition of the classic morphology of partial atrophy on routine hematoxylin and eosin-stained sections is critical to avoid misdiagnosing partial atrophy as adenocarcinoma.

[MeSH-major] Adenocarcinoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

[MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Middle Aged

MedlinePlus Health Information. consumer health - Prostate Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18408595.001).

[ISSN] 1532-0979

[Journal-full-title] The American journal of surgical pathology

[ISO-abbreviation] Am. J. Surg. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Immunolabeling pattern of cytokeratin 19 expression may distinguish sebaceous tumors from basal cell carcinomas.

BACKGROUND: Distinction between sebaceous tumors and basal cell carcinomas can often pose diagnostic problems.

Our aim was to evaluate the use of CK 19 staining patterns in differentiating between sebaceous tumors and basal cell carcinomas.

METHODS: Thirty-seven cases including 5 sebaceous adenomas, 16 sebaceous epitheliomas, 6 sebaceous carcinomas and 14 basal cell carcinomas (7 being of the morpheaform type and 7 nodular basal cell carcinomas) were tested with a monoclonal mouse antibody to human CK 19.

CK 19 was found to be strongly positive in 9/14 (64%) and focally positive in 2/14 (14%) of basal cell carcinomas.

CONCLUSION: CK 19 expression can be helpful in differentiating sebaceous tumors (including sebaceous adenomas, sebaceous epitheliomas and sebaceous carcinomas) from basal cell carcinomas and may be a useful adjunct when these entities are included in the differential diagnosis.

[MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Adenoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / diagnosis. Keratin-19 / analysis. Sebaceous Gland Neoplasms / diagnosis. Sebaceous Glands / pathology

[MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Humans. Middle Aged

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18095993.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Histologic examination showed a lobular, folliculocentric proliferation of palely eosinophilic to clear cells surrounded by peripheral basal cells with palisading.

Therefore, DTL should enter the differential diagnosis of clear-cell neoplasms on the eyelid.

[MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Eyelid Neoplasms / diagnosis. Hair Diseases / diagnosis. Hair Follicle / pathology. Skin Neoplasms / diagnosis

[MeSH-minor] Antigens, CD34 / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Glycogen / metabolism. Humans. Male. Middle Aged

MedlinePlus Health Information. consumer health - Hair Problems.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17997733.001).

[ISSN] 1600-0560

[Journal-full-title] Journal of cutaneous pathology

[ISO-abbreviation] J. Cutan. Pathol.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Denmark

[Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 9005-79-2 / Glycogen

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing rapidly in the developed world.

Therefore we have examined the activation of Akt in Barrett's oesophagus and oesophageal adenocarcinoma and the functional effects of Akt activation in vitro.

The functional effects of Akt were examined using Barrett's adenocarcinoma cells in culture.

RESULTS: In normal squamous oesophagus, erosive oesophagitis and non-dysplastic Barrett's oesophagus, phospho-Akt was limited to the basal 1/3 of the mucosa.

Image analysis confirmed that Akt activation was significantly increased in non-dysplastic Barrett's oesophagus compared to squamous epithelium and further significantly increased in high-grade dysplasia and adenocarcinoma.

In all cases of high grade dysplasia and adenocarcinoma Akt was activated in the luminal 1/3 of the epithelium.

CONCLUSION: Akt is abnormally activated in Barrett's oesophagus, high grade dysplasia and adenocarcinoma.

Akt activation promotes proliferation and inhibits apoptosis in Barrett's adenocarcinoma cells and both transient acid exposure and leptin stimulate Akt phosphorylation.

Activation of Akt in obesity and by reflux of gastric acid may be important in the pathogenesis of Barrett's adenocarcinoma.

[MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Cell Transformation, Neoplastic / metabolism. Enzyme Activation / physiology. Esophageal Neoplasms / enzymology. Proto-Oncogene Proteins c-akt / metabolism

[MeSH-minor] Apoptosis. Cell Proliferation. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Precancerous Conditions / enzymology. Precancerous Conditions / pathology

MedlinePlus Health Information. consumer health - Esophageal Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2002 Aug 2;277(31):27613-21 [12000750.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Aug;283(2):G327-34 [12121879.001]

[Cites] Gastroenterology. 2003 Mar;124(3):615-25 [12612900.001]

[Cites] J Surg Res. 2003 Jul;113(1):50-5 [12943810.001]

[Cites] J Biol Chem. 2003 Sep 12;278(37):34783-93 [12826665.001]

[Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]

[Cites] Cancer Res. 2004 Mar 1;64(5):1561-9 [14996709.001]

[Cites] Cancer Res. 2004 Mar 15;64(6):1915-9 [15026323.001]

[Cites] J Biol Chem. 2004 Apr 16;279(16):16495-502 [14752104.001]

[Cites] Br J Cancer. 2004 Aug 16;91(4):714-9 [15266314.001]

[Cites] Biochem Biophys Res Commun. 2004 Oct 8;323(1):44-8 [15351698.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Oct;287(4):G743-8 [15231484.001]

[Cites] Life Sci. 2004 Nov 5;75(25):2983-95 [15474551.001]

[Cites] J Clin Oncol. 2004 Oct 15;22(20):4217-26 [15483033.001]

[Cites] Am J Clin Pathol. 1995 Mar;103(3):295-9 [7872251.001]

[Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]

[Cites] Gastroenterology. 1996 Jul;111(1):85-92 [8698230.001]

[Cites] J Clin Invest. 1996 Nov 1;98(9):2120-8 [8903332.001]

[Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]

[Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]

[Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]

[Cites] J Biol Chem. 1999 Jun 11;274(24):16741-6 [10358014.001]

[Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]

[Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]

[Cites] Am J Gastroenterol. 1999 Aug;94(8):2043-53 [10445526.001]

[Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]

[Cites] Gut. 2005 Mar;54 Suppl 1:i21-6 [15711004.001]

[Cites] Gut. 2005 Mar;54 Suppl 1:i27-32 [15711005.001]

[Cites] Gastroenterology. 2005 May;128(5):1471-505 [15887129.001]

[Cites] J Surg Res. 2005 Jul 1;127(1):53-8 [15964304.001]

[Cites] Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):106-12 [16265072.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G991-7 [16081761.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Feb;290(2):G335-42 [16239404.001]

[Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):140-9 [16442704.001]

[Cites] Regul Pept. 2006 Mar 15;134(1):1-8 [16169610.001]

[Cites] Endocrinology. 2006 Sep;147(9):4505-16 [16740977.001]

[Cites] Int J Colorectal Dis. 2007 Apr;22(4):401-9 [16912864.001]

[Cites] Br J Surg. 2007 Mar;94(3):346-54 [17212381.001]

[Cites] Exp Cell Res. 1999 Nov 25;253(1):210-29 [10579924.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Feb;280(2):G298-307 [11208554.001]

[Cites] Br J Cancer. 2001 Mar 23;84(6):748-53 [11259087.001]

[Cites] Gastroenterology. 2002 Feb;122(2):299-307 [11832445.001]

[Cites] Am J Gastroenterol. 2002 Jun;97(6):1319-27 [12094844.001]

[Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]

[Cites] Gut. 2003 Feb;52(2):174-80 [12524396.001]

(PMID = 17559672.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-akt

[Other-IDs] NLM/ PMC1899509

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.

We investigated the ability of the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) to interact with gemcitabine (GEM) in inducing pancreatic cancer cell death.

The combined treatment with TSA and GEM synergistically inhibited growth of four pancreatic adenocarcinoma cell lines and induced apoptosis.

The functional role of ROS in cell growth inhibition by GEM was supported by (i) a significantly reduced GEM-associated growth inhibition by the free radical scavenger N-acetyl-L-cysteine, and (ii) a positive correlation between the basal level of ROS and sensitivity to GEM in 10 pancreatic cancer cell lines.

The functional role of both Bim and 5'-nucleotidase UMPH type II in cell growth inhibition by TSA and GEM was assessed by RNA interference assays.

In vivo studies on xenografts of pancreatic adenocarcinoma cells in nude mice showed that the association of TSA and GEM reduced to 50% the tumour mass and did not cause any apparent form of toxicity, while treatments with TSA or GEM alone were ineffective.

[MeSH-major] Adenocarcinoma / metabolism. Cell Proliferation / drug effects. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors. Hydroxamic Acids. Pancreatic Neoplasms / metabolism

[MeSH-minor] 5'-Nucleotidase / genetics. 5'-Nucleotidase / metabolism. Animals. Apoptosis / physiology. Apoptosis Regulatory Proteins / metabolism. Cell Cycle / physiology. Cell Line, Tumor. Glycoproteins / genetics. Glycoproteins / metabolism. Histone Deacetylase Inhibitors. Humans. Membrane Proteins / metabolism. Mice. Proto-Oncogene Proteins / metabolism. Reactive Oxygen Species / metabolism

MedlinePlus Health Information. consumer health - Pancreatic Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17555830.001).

[ISSN] 0006-3002

[Journal-full-title] Biochimica et biophysica acta

[ISO-abbreviation] Biochim. Biophys. Acta

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Enzyme Inhibitors; 0 / Glycoproteins; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / Reactive Oxygen Species; 0W860991D6 / Deoxycytidine; 3X2S926L3Z / trichostatin A; B76N6SBZ8R / gemcitabine; EC 3.1.3.5 / 5'-Nucleotidase; EC 3.1.3.5 / NT5C3 protein, human

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-minor] Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Female. Follow-Up Studies. Humans. Male. Melanoma / radiotherapy. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Retrospective Studies. Sarcoma / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden / radiation effects

MedlinePlus Health Information. consumer health - Head and Neck Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17434110.001).

[ISSN] 1538-4721

[Journal-full-title] Brachytherapy

[ISO-abbreviation] Brachytherapy

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The use of transgenic and knockout gene technologies with mice is unraveling some of the specific genes regulating fate determination in stem cells other than squamous lineage, including basal cell carcinoma and sebaceous adenomas.

The following review examines the evidence for the stem cell origin of epidermal tumors and the contribution of some specific gene families toward stem cell fate decisions during epidermal tumor progression.

[MeSH-major] Adenocarcinoma, Sebaceous / genetics. Carcinoma, Basal Cell / genetics. Epidermis. Epigenesis, Genetic. Neoplastic Stem Cells. Skin Neoplasms / genetics

MedlinePlus Health Information. consumer health - Skin Cancer.

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12483-8 [12221288.001]

[Cites] Nat Genet. 2000 Sep;26(1):114-7 [10973262.001]

[Cites] Development. 2004 Apr;131(8):1787-99 [15084463.001]

[Cites] Dev Biol. 1999 Jan 1;205(1):1-9 [9882493.001]

[Cites] Cancer Res. 1988 Nov 15;48(22):6285-90 [2460219.001]

[Cites] EMBO J. 1997 May 1;16(9):2365-75 [9171350.001]

[Cites] Exp Biol Med (Maywood). 2001 Sep;226(8):753-7 [11520941.001]

[Cites] Curr Biol. 2001 Apr 17;11(8):558-68 [11369200.001]

[Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]

[Cites] Exp Cell Res. 2004 Apr 15;295(1):79-90 [15051492.001]

[Cites] J Invest Dermatol. 1999 Apr;112(4):470-5 [10201531.001]

[Cites] Nat Genet. 1999 Apr;21(4):410-3 [10192393.001]

[Cites] J Invest Dermatol. 2003 Apr;120(4):501-11 [12648211.001]

[Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]

[Cites] Cell. 2001 Jan 26;104(2):233-45 [11207364.001]

[Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7822-6 [8052666.001]

[Cites] Stem Cells. 2002;20(1):21-31 [11796919.001]

[Cites] J Invest Dermatol. 1994 Nov;103(5 Suppl):90S-95S [7963691.001]

[Cites] Oncogene. 2001 Aug 30;20(38):5341-9 [11536046.001]

[Cites] Cancer Res. 1993 Jul 1;53(13):2961-4 [8319202.001]

[Cites] Cancer Res. 1993 Oct 15;53(20):4803-10 [8402665.001]

[Cites] J Dermatol. 2004 May;31(5):368-75 [15187303.001]

[Cites] Nat Biotechnol. 2004 Apr;22(4):411-7 [15024388.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4742-7 [10758156.001]

[Cites] J Invest Dermatol. 1993 Oct;101(4):591-4 [8409528.001]

[Cites] Science. 2004 Jan 16;303(5656):359-63 [14671312.001]

[Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10960-5 [11005869.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100 Suppl 1:11873-80 [12917489.001]

[Cites] Cell Tissue Res. 1985;242(3):551-6 [2416451.001]

[Cites] Mol Carcinog. 1997 Sep;20(1):151-8 [9328446.001]

[Cites] Cell. 2004 Sep 3;118(5):635-48 [15339667.001]

[Cites] J Invest Dermatol. 1996 Apr;106(4):759-65 [8618017.001]

[Cites] Cell. 1993 May 21;73(4):713-24 [8500165.001]

[Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]

[Cites] Hum Mol Genet. 2003 Nov 15;12(22):2931-40 [14506134.001]

[Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]

[Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]

[Cites] EMBO J. 2003 Jun 16;22(12):2981-91 [12805213.001]

[Cites] Cancer Res. 1986 Jun;46(6):3061-6 [3698024.001]

[Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]

[Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]

[Cites] J Cell Biol. 2000 Sep 4;150(5):1149-60 [10974002.001]

[Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]

[Cites] Cancer. 1999 Nov 15;86(10):2038-44 [10570429.001]

[Cites] J Invest Dermatol. 2001 May;116(5):739-42 [11348463.001]

[Cites] J Invest Dermatol. 2000 Nov;115(5):788-94 [11069615.001]

[Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]

[Cites] Cell. 1990 Jun 29;61(7):1329-37 [2364430.001]

[Cites] J Cell Sci. 1978 Feb;29:249-69 [627606.001]

[Cites] Mol Cell Biol. 2004 Feb;24(4):1608-13 [14749376.001]

[Cites] EMBO J. 2001 Jun 1;20(11):2619-30 [11387197.001]

[Cites] Carcinogenesis. 1991 Jun;12(6):1119-24 [2044193.001]

[Cites] EMBO J. 2001 Mar 15;20(6):1215-22 [11250888.001]

[Cites] Mol Carcinog. 1993;7(2):99-110 [7681293.001]

[Cites] Cancer Res. 1997 Aug 15;57(16):3436-43 [9270010.001]

[Cites] J Invest Dermatol. 1999 Oct;113(4):595-9 [10504446.001]

[Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]

[Cites] Differentiation. 2004 Oct;72(8):371-80 [15606496.001]

[Cites] Cancer Res. 2000 Jan 15;60(2):226-9 [10667563.001]

[Cites] J Invest Dermatol. 1998 Dec;111(6):1045-52 [9856815.001]

[Cites] Nature. 1983 Jul 7-13;304(5921):69-71 [6408484.001]

[Cites] Int J Cancer. 1987 Jun 15;39(6):778-84 [3294611.001]

[Cites] Genes Dev. 2005 Jan 15;19(2):214-23 [15625189.001]

[Cites] Cell. 2000 Aug 18;102(4):451-61 [10966107.001]

[Cites] Dev Biol. 2003 Nov 15;263(2):203-15 [14597196.001]

[Cites] J Invest Dermatol. 2003 Nov;121(5):963-8 [14708593.001]

[Cites] J Cell Sci. 1996 May;109 ( Pt 5):1017-28 [8743949.001]

[Cites] Cell. 2001 May 18;105(4):533-45 [11371349.001]

[Cites] Cell Biol Int. 2004;28(7):523-9 [15261160.001]

[Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]

[Cites] Curr Biol. 1998 Apr 23;8(9):516-24 [9560338.001]

[Cites] Cancer Detect Prev. 1996;20(1):20-30 [8907200.001]

[Cites] Nat Genet. 2001 Jun;28(2):165-8 [11381265.001]

[Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]

[Cites] Mol Cell Biol. 2000 Feb;20(4):1436-47 [10648628.001]

[Cites] Pathol Res Pract. 1994 Oct;190(9-10):950-4 [7899145.001]

[Cites] Development. 2002 Jan;129(1):95-109 [11782404.001]

[Cites] J Cutan Pathol. 1994 Dec;21(6):500-6 [7699116.001]

[Cites] J Invest Dermatol. 2003 Nov;121(5):1095-103 [14708612.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3156-61 [11248048.001]

[Cites] Am J Pathol. 2003 Dec;163(6):2173-8 [14633591.001]

[Cites] J Cell Sci. 1998 Nov;111 ( Pt 21):3179-88 [9763512.001]

[Cites] Oncogene. 1996 Feb 15;12(4):765-73 [8632898.001]

[Cites] J Invest Dermatol. 1997 Jan;108(1):113-7 [8980299.001]

[Cites] Cancer Res. 1984 Sep;44(9):3779-82 [6430553.001]

[Cites] J Natl Cancer Inst. 1986 Jan;76(1):151-8 [3455737.001]

[Cites] Am J Pathol. 1997 May;150(5):1791-803 [9137102.001]

[Cites] Mol Cell. 1999 May;3(5):565-77 [10360173.001]

[Cites] Br J Cancer. 1999 Jul;80 Suppl 1:28-33 [10466758.001]

[Cites] Trends Mol Med. 2004 Dec;10(12):577-80 [15567325.001]

[Cites] Cell. 1990 Aug 24;62(4):697-708 [1696852.001]

[Cites] Acta Derm Venereol. 1994 Mar;74(2):101-5 [7911612.001]

(PMID = 17142859.001).

[ISSN] 1550-8943

[Journal-full-title] Stem cell reviews

[ISO-abbreviation] Stem Cell Rev

[Language] eng

[Grant] United States / Intramural NIH HHS / /

[Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review

[Publication-country] United States

[Number-of-references] 92